ERBB2 and neoplasm: Exemplary strategies include (i) monoclonal antibodies (mAbs) directed at tumor-associated antigens and markers (e.g., human epidermal growth factor receptor 2 [HER2] and CD20); (ii) stimulation of effector leukocytes by means of immune checkpoint inhibitors (ICIs); and (iii) adoptive cell transfer of genetically engineered immune cells (e.g., chimeric antigen receptor T cells; CAR-T cells) (3, 4).